Endocrine & metabolic PGx.
Information for hormone and diabetes care. A gene panel for diabetes medications, estrogen-containing birth control and other metabolic therapies — including the inherited clotting risks that matter for hormone use. One saliva sample, run in our CLIA-certified lab, with results your prescriber can refer back to.
- One sample, no blood draw
- Results in 3–7 business days
- Share with any prescriber
Panel
7 genes
Sample
Saliva or cheek swab
Results
3–7 business days
Price
From $289
What we test
Panel medications.
See how your genes may affect your response to certain medications. Review your results with your prescriber.
Metformin — ATM
Response varies with genotype; a documented result helps when metformin has underperformed.
Glimepiride, gliclazide, glibenclamide, tolbutamide — CYP2C9
Poor CYP2C9 metabolizers can hit low blood sugar at standard sulfonylurea doses.
Saxagliptin — CYP3A4
DPP-4 inhibitor levels depend on CYP3A4 metabolism.
Estrogen-containing oral contraceptives — FV, FII, MTHFR
Inherited clotting variants raise the risk of thrombosis on estrogen — worth knowing before choosing a contraceptive.
Eliglustat — CYP2D6
Dosing of this Gaucher disease therapy is directly guided by CYP2D6 metabolizer status.
Who this is for
Genes can raise the risk of low blood sugar or blood clots on standard therapy.
Diabetes medications
Starting or adjusting treatment for type 2 diabetes, especially after a low-blood-sugar episode.
Considering estrogen-containing birth control
Inherited clotting risk is relevant before starting estrogen therapy.
A clotting history
Yours or in close relatives — the FV and FII results inform hormone decisions.
Is this test right for you?
You take or are starting a medication for type 2 diabetes.
You had low blood sugar on a standard sulfonylurea dose.
You are considering estrogen-containing birth control.
You or close relatives have had blood clots.
Metformin has not worked as expected for you.
Your endocrinologist or provider suggested genetic testing.
Answering yes to even one of these is a good reason to test before the next prescription change.
Before you order
Total price
From $289
One-time price, shown in full at checkout before you pay. No separate fee for the kit, return shipping or the healthcare provider order.
What's included
Kit to report
A saliva or cheek-swab kit with instructions, a prepaid return label, the healthcare provider order, genetic testing in our lab and a gene-drug report in your secure portal.
Who orders the test
A licensed healthcare provider
A licensed healthcare provider in our network reviews your request and places the order during checkout, at no extra cost. No referral needed.
Who reviews the results
A board-certified geneticist
Every report is reviewed and signed in our lab by a board-certified molecular geneticist before it is released.
The science
What the evidence says about getting tested.
Diabetes and hormone therapies interact with genes in two very different ways. Drug-metabolism genes such as CYP2C9 change how quickly sulfonylureas are cleared, which is why the same dose can cause low blood sugar in one person and nothing in another. Separately, inherited clotting variants such as Factor V Leiden change how risky estrogen-containing contraception is — a decision clinicians weigh against family history every day.
About 1 in 20
people are CYP2C9 poor metabolizers, who can develop low blood sugar at standard sulfonylurea doses.
Source: CYP2C9 pharmacogenetics literature
≈5%
of people of European ancestry carry Factor V Leiden — the most common inherited clotting risk relevant to estrogen therapy.
Source: MedlinePlus Genetics
2–6×
higher risk of venous thromboembolism with estrogen-containing contraceptives compared with non-use — compounded by inherited clotting variants.
Source: CDC U.S. MEC criteria
Documented
of metformin response variability is linked to inherited differences in drug response genes, including the ATM locus rs11212617.
Source: Metformin pharmacogenetics studies
How often should you test?
Test once — your genotype doesn't change. The highest-value moments are before starting or switching diabetes medication, before choosing an estrogen-containing contraceptive, and when metformin has not performed as expected and you want documented evidence for your prescriber.
References
- MedlinePlus Genetics — Factor V Leiden thrombophilia: inheritance, prevalence and venous clot risk.
- CDC — U.S. Medical Eligibility Criteria for Contraceptive Use: venous thromboembolism risk with estrogen-containing contraception.
- PubMed literature — metformin response and the ATM locus (GoDARTS pharmacogenetic studies).
- PubMed literature — CYP2C9 metabolizer status and sulfonylurea hypoglycemia.
Population data
How common is each metabolizer type?
Published population frequencies for the cytochrome P450 enzymes read on this panel. Your report places you in one of these groups for each enzyme.
| Cytochrome | Poor metabolizer | Intermediate metabolizer | Normal metabolizer | Rapid or ultra-rapid metabolizer |
|---|---|---|---|---|
| CYP2D6 | 4–7% | 9–35% | 50–90% | 2–3% |
| CYP2C9 | 3% | 30% | 68% | N/A |
| CYP2C19 | 2–20% | 24–36% | 14–44% | 30% |
Population frequencies compiled from CPIC guidelines and FDA pharmacogenomic biomarker tables; frequencies vary by ancestry.
Questions people actually ask
Bring data to your next endocrinology visit.
One sample, one flat price, a report your prescribers can refer back to.